some thoughts, page-3

Hi guys, there is no suggestion that Tibotec had anything to do with AVX capital raising. This is purely a capital raising to strengthen the balance sheet for the end of year accounts.

Tibotec are at this stage purely interested in licensing the HIV integrase program. We should not confuse this with partnering ATC.
They have had nothing to do with the closing of Phase 3 testing on ATC. This was lobbied for by avx in order to determine the most effective path to commercialisation, its justification is on the basis that ATC has completed equal to or more Phase 3 testing than all HIV drugs recently approved. However the most likely outcome from the "unblinding" is a partial approval with ongoing testing.

The company are more convinced than ever that ATC is "The Jewel in the crown of the Biotec industry in Australia"

As shareholders we now have the security and options that a strong balance sheet provides and a unique product.